

Supplemental Appendix for

**Weak antibody response to 3 doses of mRNA vaccine in kidney transplant recipients
treated with belatacept**

Table of contents

SUPPLEMENTAL RESULTS Page 2
Supplemental Table 1 Page 2

Table 1: Baseline characteristics and post-vaccinal humoral responses of the 62 KTRs converted to belatacept and 35 non-belatacept-treated KTRs, who received 3 injections of BNT162b2 mRNA COVID-19 vaccine.

Variables	Belatacept group, N=62	Control group, N=35	p-value
Age, median (IQR)	63.5 (51-72)	51 (45-61.5)	0.007
Sex (Males), N (%)	36 (58)	14 (40)	0.19
KT > 1, N (%)	6 (10)	4 (11)	0.50
Induction Immunosuppressive therapy			
Antithymocyte globulin, N (%)	20 (32)	13 (39)	0.42
Basiliximab, N (%)	42 (68)	19 (58)	
Rituximab at induction, N (%)	10 (16)	5 (14)	
Maintenance immunosuppressive therapy			
Calcineurin inhibitors, N (%)	2 (3)	35 (100)	<0.0001
Azathioprine, N (%)	3 (5)	2 (6)	1.00
Mycophenolic acid, N (%)	44 (71)	28 (82)	0.15
Dose, median (IQR)	1000 (750-1500)	1000 (750-1250)	0.42
mTOR-i (Everolimus), N (%)	8 (13)	2 (6)	0.49
Steroids, N (%)	62 (100)	33 (94)	0.93
Dose, median (IQR)	7.5 (5-10)	5 (5-8.125)	0.06
Belatacept, N (%)	62 (100)	0 (0)	<0.0001
SCr at vaccine, median (IQR)	137 (105.1-180)	128 (105.0-153.1)	0.81
eGFR at vaccine, median (IQR)	44.4 (33.2-59.7)	47 (34.5-62.0)	0.73
At third vaccine injection			
Time between KT and 3rd injection (years)	4.8 (2.4-701)	3.5 (1.7-7.8)	0.69
Time between 3rd injection and serology, days, median (IQR)	28 (28-33)	34 (28-49)	0.02
Positive serology after 3 injections, N (%)	4 (6.4)	13 (37)	0.0001

eGFR: estimated glomerular filtration rate, **IQR:** interquartile range, **KT:** kidney transplantation, **SCr:** serum creatinine